Tofogliflozin
CAS: 903565-83-3
Ref. 3D-FT28301
| 1mg | 189.00 € | ||
| 2mg | 239.00 € | ||
| 5mg | 440.00 € | ||
| 10mg | 569.00 € | ||
| 25mg | 949.00 € |
Product Information
- (1S,3'R,4'S,5'S,6'R)-6-[(4-Ethylphenyl)methyl]-3',4',5',6'-tetrahydro-6'-(hydroxymethyl)spiro[isobenzofuran-1(3H),2'-[2H]pyran]-3',4 ',5'-triolCSG 452
- (1S,3'R,4'S,5'S,6'R)-6-[(4-Ethylphenyl)methyl]-3',4',5',6'-tetrahydro-6'-(hydroxymethyl)-spiro[isobenzofuran-1(3H),2'-[2H]pyran]-3',4',5'-triol
- (1S,3′R,4′S,5′S,6′R)-6-[(4-Ethylphenyl)methyl]-3′,4′,5′,6′-tetrahydro-6′-(hydroxymethyl)spiro[isobenzofuran-1(3H),2′-[2H]pyran]-3′,4′,5′-triol
- Csg 452
- R-7201
- Spiro[isobenzofuran-1(3H),2′-[2H]pyran]-3′,4′,5′-triol, 6-[(4-ethylphenyl)methyl]-3′,4′,5′,6′-tetrahydro-6′-(hydroxymethyl)-, (1S,3′R,4′S,5′S,6′R)-
Tofogliflozin is a glucose-lowering drug that acts as an inhibitor of sodium-glucose transport (SGLT2) in the proximal tubule. It is used for the treatment of type 2 diabetes mellitus and other metabolic disorders, including hepatic impairment. Tofogliflozin has been shown to be effective for reducing systolic blood pressure in patients with hypertension. This drug also reduces histological evidence of disease activity and p-hydroxybenzoic acid levels in patients with active rheumatoid arthritis or psoriatic arthritis. Tofogliflozin has been shown to increase insulin sensitivity, which may be due to its ability to activate growth factor-β1 and GLP-1 receptors in adipose tissue.
Chemical properties
Technical inquiry about: 3D-FT28301 Tofogliflozin
If you want to request a quotation or place an order, please instead add the desired products to your cart and then request a quotation or order from the cart. It is faster, cheaper, and you will be able to benefit from the available discounts and other advantages.
